Strides Pharma Science Ltd Share Price (STAR)

Strides Pharma Subsidiary Receives FDA Approval for Antidepressant Medication - 09 Apr, 2024

Strides Pharma Science's subsidiary, Strides Pharma Global, has received USFDA approval for Fluoxetine Tablet, complementing the existing approval of Fluoxetine capsules. The product is bioequivalent and therapeutically equivalent to Eli Lilly's Prozac Tablets. The market size for Fluoxetine tablets is approximately $23.9 million, according to IMS. The company plans to launch ~60 new products over three years in the US.

Strides Pharma Hits 52-Week High Despite USFDA Observations - 08 Apr, 2024

Shares of Strides Pharma Science Ltd reached a 52-week high despite USFDA observations on its subsidiary's Chennai facility. The company will respond comprehensively within the stipulated time. In Q2FY24, Strides Pharma recorded a net loss of ₹131.3 crore but experienced YoY revenue growth of 11.4%. Shares were trading at Rs 843.35 on the BSE.

USFDA Inspection Finds Observations at Strides Alathur Facility - 06 Apr, 2024

The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the Formulations Facility of Strides Alathur, resulting in two observations. Strides Pharma Science has pledged to address these observations within the stipulated timeframe.

Strides Pharma Science Ltd's P/S Ratio Lower Than Industry Median - 04 Apr, 2024

Strides Pharma Science Ltd's P/S ratio of 1.9x is lower than the median P/S ratio of close to 2.4x in the Pharmaceuticals industry in India. The company's recent revenue growth has been in line with the industry, and if this continues, existing shareholders won't be losing sleep over the current share price.